Klinische Wochenschrift

, Volume 65, Issue 18, pp 852–859 | Cite as

Lupus anticoagulant associated syndrome in benign and malignant systemic disease — Analysis of ten observations

  • U. Dührsen
  • D. Paar
  • C. Kölbel
  • A. Boekstegers
  • U. Metz-Kurschel
  • R. Wagner
  • W. Kirch
  • P. Meusers
  • E. König
  • G. Brittinger


The clinical and laboratory findings in seven female patients with primary autoimmune diseases, one female patient with lymphoplasmacytoid (LP) immunocytoma and IgM paraproteinemia, and two male patients with multiple myeloma are described. The common denominator in all patients was a lupus anticoagulant or a closely related coagulation disorder. Recurrent thrombosis was observed in six patients with autoimmune diseases and in two patients with malignant monoclonal gammopathies. Other clinical manifestations included cerebral disorders (four patients with autoimmune disease/two patients with monoclonal gammopathy), repeated obstetric complications (6/1), asymptomatic valvular heart disease (6/1), renal dysfunction (6/2), hepatic involvement (2/2), and arthropathy (2/0). Laboratory investigations revealed a biologic false-positive serological test for syphilis in six patients with autoimmune disease and one with monoclonal gammopathy, antinuclear antibodies (4/0), antibodies against DNA (4/1), and a positive direct Coombs test (3/1) which was accompanied by hemolytic anemia in two patients (1/1). Additionally slight leucocytopenia (2/1) and thrombocytopenia (6/2) were observed; abnormal bleeding was only seen in one patient with severe thrombocytopenia. Other complications characteristic of LP immunocytoma or multiple myeloma were missing.

The obvious similarities between the patients with autoimmune diseases and the patients with malignant monoclonal gammopathies suggest analogous pathogenetic mechanisms. Since the clinical syndrome associated with the lupus anticoagulant in patients with autoimmune disorders has been proposed to arise from the action of autoantibodies against phospholipids, it is attractive to hypothesize that the findings in the patients with malignant diseases were caused by an autoantibody activity of the monoclonal immunoglobulin. This assumption is substantiated by the observation that in one patient the paraprotein level correlated with the prolongation of the coagulation times and the severeness of the clinical perturbations. Although paraproteins mimicking the laboratory alterations of the lupus anticoagulant have been reported before, the corresponding clinical features have not yet been described in malignant monoclonal gammopathies. The syndrome may be juxtaposed to other systemic disorders complicating paraproteinemias, and is possibly more frequent than is as yet known.

Key words

Lupus anticoagulant Paraproteinemia Systemic lupus erythematosus Multiple myeloma Lymphoproliferative diseases Lymphoma 



Activated partial thromboplastin time


Biologic false-positive serological test for syphilis


Deoxyribonucleic acid


Chronic glomerulonephritis


Lymphoplasmacytoid immunocytoma


Lupus anticoagulant

LP immunocytoma

Lymphoplasmacytoid immunocytoma


Multiple myeloma


Panarteritis nodosa

POEMS syndrome

Polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes


Prothrombin time


Systemic lupus erythematosus


Venereal Disease Research Laboratory


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL (1980) Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Medicine 59:311–322Google Scholar
  2. 2.
    Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GRV (1983) Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 287:1021–1023Google Scholar
  3. 3.
    Boxer M, Ellman L, Carvalho A (1976) The lupus anticoagulant. Arthr Rheum 19:1244–1248Google Scholar
  4. 4.
    Coleman M, Vigliano EM, Weksler ME, Nachman RL (1972) Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood 39:210–223Google Scholar
  5. 5.
    Cooper MR, Cohen HJ, Huntley CC, Waite BM, Spees L, Spurr CL (1974) A monoclonal IgM with antibody-like specificity for phospholipids in a patient with lymphoma. Blood 43:493–504Google Scholar
  6. 6.
    Dighiero G, Guilbert B, Fermand J-P, Lymberi P, Danon F, Avrameas S (1983) Thirty-six human monoclonal immunoglobulins with antibody activity against cytoskeletal proteins, thyroglobulin, and native DNA: immunologic studies and clinical correlations. Blood 62:264–270Google Scholar
  7. 7.
    Drusin LM, Litwin SD, Armstrong D, Webster BP (1974) Waldenström's macroglobulinemia in a patient with a chronic biologic false-positive test for syphilis. Am J Med 56:429–432Google Scholar
  8. 8.
    Dührsen U, Paar D, Brittinger G (1987) Lupus anticoagulant associated syndrome in benign and malignant systemic disease. First of two parts: review of the literature. Klin Wochenschr 65:818–822Google Scholar
  9. 9.
    Editorial (1972) Autoantibodies to serum lipoproteins. Br Med J 4:380–381Google Scholar
  10. 10.
    Elias M, Eldor A (1984) Thromboembolism in patients with the ‘lupus’-type circulating anticoagulant. Arch Intern Med 144:510–515Google Scholar
  11. 11.
    Fudenberg HH (1971) Genetically determined immune deficiency as the predisposing cause of ‘autoimmunity’ and lymphoid neoplasia. Am J Med 51:295–298Google Scholar
  12. 12.
    Greene MH (1980) Clinical and environmental factors. In: Berard, C.W., moderator: A multidisciplinary approach to non-Hodkin's lymphomas. Ann Intern Med 94:218–222Google Scholar
  13. 13.
    Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet II:1211–1214Google Scholar
  14. 14.
    Hughes GRV (1984) Connective tissue disease and the skin. Clin Exp Dermatol 9:535–544Google Scholar
  15. 15.
    Jordan E, Burnstein SL, Calabro JJ, Henderson ES (1978) Multiple myeloma complicating the course of seronegative systemic lupus erythematosus. Arthr Rheum 21:260–263Google Scholar
  16. 16.
    Lafer EM, Rauch J, Andrzejewski C jr, Mudd D, Furie B, Furie B, Schwartz RS, Stollar BD (1981) Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids. J Exp Med 153:897–909Google Scholar
  17. 17.
    Lechner K (1974) Acquired inhibitors in nonhemophilic patients. Haemostasis 3:65–93Google Scholar
  18. 18.
    Lechner K, Pabinger-Fasching I (1985) Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis 15:254–262Google Scholar
  19. 19.
    Long LA, Riopelle JL, Francoeur M, Pare A, Poirier P, Georgesco M, Colpron G (1955) Macroglobulinaemia. Effect of macroglobulins on prothrombin conversion accelerators. Can Med Assoc J 73:726–733Google Scholar
  20. 20.
    Metzger H (1969) Myeloma proteins and antibodies. Am J Med 47:837–844Google Scholar
  21. 21.
    Miller JL, Brodey M, Hill JH (1957) Studies on significance of biologic false-positive reaction. JAMA 164:1461–1465Google Scholar
  22. 22.
    Mueh JR, Herbst KD, Rapaport SI (1980) Thrombosis in patients with the lupus anticoagulant. Ann Intern Med 92 (Part 1):156–159Google Scholar
  23. 23.
    Nihléhn J-E, Nilsson IM (1966) Coagulation studies in different types of myeloma. Acta Med Scand [Suppl] 445:194–199Google Scholar
  24. 24.
    Potter M (1971) Myeloma proteins (M-components) with antibody-like activity. N Engl J Med 284:831–838Google Scholar
  25. 25.
    Rubin L, Urowitz MB, Pruzanski W (1984) Systemic lupus erythematosus with paraproteinemia. Arthr Rheum 27:638–644Google Scholar
  26. 26.
    Schleider MA, Nachman RL, Jaffe EA, Coleman M (1976) A clinical study of the lupus anticoagulant. Blood 48:499–509Google Scholar
  27. 27.
    Seligmann M, Brouet JC (1973) Antibody activity of human myeloma globulins. Sem Hematol 10:163–177Google Scholar
  28. 28.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Green Schaller J, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum 25:1271–1277Google Scholar
  29. 29.
    Thiagarjan P, Shapiro SS, De Marco L (1980) Monoclonal immunoglobulin Mλ coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 66:397–405Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • U. Dührsen
    • 1
    • 2
  • D. Paar
    • 1
  • C. Kölbel
    • 1
  • A. Boekstegers
    • 1
  • U. Metz-Kurschel
    • 1
  • R. Wagner
    • 1
  • W. Kirch
    • 1
  • P. Meusers
    • 1
  • E. König
    • 1
  • G. Brittinger
    • 1
  1. 1.Medizinische Klinik und Poliklinik der Universität (GHS) EssenGermany
  2. 2.The Walter and Eliza Hall Institute of Medical Research Cancer Research Unit Post OfficeThe Royal Melbourne HospitalVictoriaAustralia

Personalised recommendations